Cargando…
Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay
To investigate the effects of hydroxychloroquine (HCQ) drug use on the risk of pulmonary vascular disease (PVD) in an interstitial lung disease cohort (ILD cohort, ILD+ virus infection), we retrospectively enrolled the ILD cohort with HCQ (HCQ users, N = 4703) and the ILD cohort without HCQ (non-HCQ...
Autores principales: | Yeh, Jun-Jun, Syue, Shih-Hueh, Sun, Yi-Fun, Yeh, Yi-Ting, Zheng, Ya-Chi, Lin, Cheng-Li, Hsu, Chung Y., Kao, Chia-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219797/ https://www.ncbi.nlm.nih.gov/pubmed/35740313 http://dx.doi.org/10.3390/biomedicines10061290 |
Ejemplares similares
-
Effects of statins and steroids on coronary artery disease and stroke in patients with interstitial lung disease and pulmonary fibrosis: A general population study
por: Yeh, Jun-Jun, et al.
Publicado: (2021) -
Polymyositis/dermatomyositis is a potential risk factor for acute respiratory failure: a pulmonary heart disease
por: Syue, Shih-Huei, et al.
Publicado: (2020) -
Statin use and Vital Organ Failure in Patients With Asthma–Chronic Obstructive Pulmonary Disease Overlap: A Time-Dependent Population-Based Study
por: Yeh, Jun-Jun, et al.
Publicado: (2019) -
Time-dependent propensity-matched general population study of the effects of statin use on cancer risk in an interstitial lung disease and pulmonary fibrosis cohort
por: Yeh, Jun-Jun, et al.
Publicado: (2021) -
Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?
por: Yeh, Jun-Jun, et al.
Publicado: (2022)